Bicyclic heterocycles as HIV-integrase inhibitors

Abstract

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Description

BACKGROUND OF THE INVENTION

Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. Recent statistics (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998), indicate that as many as 33 million people worldwide are infected with the virus. In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 1998 point to close to 6 million new infections in that year alone. In the same year there were approximately 2.5 million deaths associated with HIV and AIDS.

There are currently a number of antiviral drugs available to combat the infection. These drugs can be divided into three classes based on the viral protein they target and their mode of action. In particular, saquinavir, indinavir, ritonavir, nelfmavir and amprenavir are competitive inhibitors of the aspartyl protease expressed by HIV. Zidovudine, didanosine, stavudine, lamivudine, zalcitabine and abacavir are nucleoside reverse transcriptase inhibitors that behave as substrate mimics to halt viral cDNA synthesis. The non-nucleoside reverse transcriptase inhibitors, nevaripine, delavirdine and efavirenz inhibit the synthesis of viral cDNA via a non-competitive (or uncompetitive) mechanism. Used alone these drugs are effective in reducing viral replication. The effect is only temporary as the virus readily develops resistance to all known agents. However, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N. Engl. J. Med. 1998, 338, 853-860).

Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, approximately 30-50% of patients ultimately fail combination therapy. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the rapid turnover of HIV-1 during the course of infection combined with a high viral mutation rate. Under these circumstances incomplete viral suppression caused by insufficient drug potency, poor compliance to the complicated drug regiment as well as intrinsic pharmacological barriers to exposure provides fertile ground for resistance to emerge. More disturbing are recent findings which suggest that low-level replication continues even when viral plasma levels have dropped below detectable levels (<50 copies/mL) (Carpenter, C. C.; Cooper, D. A.; Fischl, M. A.; Gatell, J. M.; Gazzard, B. G.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schechter, M.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. JAMA 2000, 283, 381-390). Clearly there is a need for new antiviral agents, preferably targeting other viral enzymes to reduce the rate of resistance and suppress viral replication even further.

HIV expresses three enzymes, reverse transcriptase, an aspartyl protease, and integrase. All three are targets for treating AIDS and HIV infection. HIV integrase catalyzes insertion of the viral cDNA into the host cell genome, which is a critical step in the viral life cycle. HIV integrase inhibitors belonging to a class of diketo acid compounds prevented viral integration and inhibited HIV-1 replication in cells (Hazuda et al. Science 2000, 287, 646). And recently, HIV integrase inhibitors have been accepted into clinical trials for treating AIDS and HIV infection (Neamati Expert. Opin. Ther. Patents 2002, 12, 709, Pais and Burke Drugs Fut. 2002, 27, 1101).

DESCRIPTION OF THE INVENTION

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and methods for inhibiting HIV integrase and treating those infected with HIV.

One aspect of the invention is a compound of Formula I

• wherein:
• R¹ is (Ar¹)alkyl;
• R² is hydrogen, hydroxy, alkyl, or alkoxy;
• R³ is hydrogen, halo, hydroxy, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, C_4-6lactamyl, N(R⁶)SO₂R⁷, N(R⁶)COR⁷, N(R⁶)CO₂R⁷, OCOR⁷, OCO₂R⁷, OCON(R⁶)(R⁶), COR⁷, CO₂R⁶, CON(R⁶)(R⁶), SOR⁷, SO₂R⁷, SO₂N(R⁶)(R⁶), P(O)(OR⁶)₂, or Ar²;
• R⁴ is hydrogen, halo, hydroxy, cyano, alkyl, alkoxy, haloalkyl, or haloalkoxy;
• R⁵ is hydrogen, halo, hydroxy, cyano, alkyl, alkoxy, haloalkyl, or haloalkoxy;
• R⁶is hydrogen, alkyl, or cycloalkyl;
• R⁷ is alkyl or cycloalkyl;
• R⁸ is hydrogen or alkyl;
• R⁹ is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, (alkoxy)alkyl, phenyl, or benzyl, wherein phenyl and benzyl are substituted with 0-2 substituents selected from the group consisting of halo, cyano, alkyl, alkoxy, halolkyl, and haloalkoxy;
• Ar¹ is
• Ar2 is tetrazolyl, triazolyl, pyrazolyl, imidazolyl, pyrrolyl, or dioxothiazinyl, and is substituted with 0-2 substituents selected from the group consisting of amino, oxo, halo, and alkyl; and
• X—Y—Z is N(R⁹)C(R⁸)₂C(R⁸)₂, N(R⁹)C(R⁸)₂C(R⁸)₂C(R⁸)₂, or N(R⁹)C(R⁸)₂C(R⁸)₂C(R⁸)₂C(R⁸)₂;
• or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of Formula I where R¹ is

Another aspect of the invention is a compound of Formula I where R¹ is provided that R³ is not hydrogen.

Another aspect of the invention is a compound of Formula I 1 where R¹ is and R³ is C_4-6lactamyl, N(R⁶)SO₂R⁷, N(R⁶)COR⁷, N(R⁶)CO₂R⁷, OCOR⁷, OCO₂R⁷, OCON(R⁶)(R⁶), COR⁷, CO₂R⁶, CON(R⁶)(R⁶), SOR⁷, SO₂R⁷, SO₂N(R⁶)(R⁶), or Ar².

Another aspect of the invention is a compound of Formula I where R² is hydrogen.

Another aspect of the invention is a compound of Formula I where R³ is triazinyl substituted with 0-1 methyl groups; R⁴ is hydrogen, chloro, flouro, or methyl; and R⁵ is hydrogen.

Another aspect of the invention is a compound of Formula I where R⁶ is hydrogen or alkyl.

Another aspect of the invention is a compound of Formula I where R⁷is alkyl.

Another aspect of the invention is a compound of Formula I where R⁸ is hydrogen or methyl.

Another aspect of the invention is a compound of Formula I where X—Y—Z is N(R⁹)CH₂CH₂, N(R⁹)CH₂CH₂CH₂, or N(R⁹)CH₂CH₂CH₂CH₂.

Another aspect of the invention is a compound according to one of the following structures:

Another aspect of the invention is a compound according to the following structure

Another aspect of the invention is a compound of Formula I where R⁹ is alkyl, cycloalkyl, hydroxyalkyl (alkoxy)alkyl, phenyl, or benzyl.

For a compound of Formula I, any scope of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, Ar¹, Ar², and X—Y—Z can be used independently with any scope of any other variable.

“C_4-6lactamyl” means a lactam of 4 to 6 carbons, for example caprolactam.

“Dioxothiazinyl” means

Unless specified otherwise, these terms have the following meanings. “Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons. “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Alkynyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one triple bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. “Haloalkyl” and “haloalkoxy” include all halogenated isomers from monohalo to perhalo. Terms with a hydrocarbon moiety (e.g. alkoxy) include straight and branched isomers for the hydrocarbon portion. “Aryl” includes carbocyclic and heterocyclic aromatic substituents. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric forms. The invention includes all stereoisomeric forms of the compounds including enantiomers and diastereromers. Methods of making and separating stereoisomers are known in the art.

The invention includes all tautomeric forms of the compounds. An example of a tautomeric pair is shown below.

Synthetic Methods

The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. The variables shown in the synthetic schemes are distinct from and should not be confuised with the variables in the claims or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention.

Some formula I compounds can be synthesized from an appropriately substituted heterocycle I-1 according to Scheme I, where R_a and P can serve as protecting groups (see Greene, T. W. and Wutz, P. G. M. Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley and Sons, New York). When P is benzyl or substituted benzyl it can be removed by hydrogenolysis (H₂—Pd/C) or acid hydrolysis (trifluoroacetic acid) to yield intermediate I-2. I-2 can be transaminated to I-4 by reaction with amine I-3. When R_a is a lower alkyl group, R_a can be removed under ester hydrolysis conditions, such as treatment with NaOH, LiOH, or KOH to deliver the corresponding carboxylic acid I-5. Alternatively, R_a can be removed by nucleophilic displacement using NaI. When R_a is benzyl and substituted benzyl, R_a can be removed by hydrogenolysis. Intermediate I-5 can be coupled using amide bond forming reagents such as DCC, PyBOP, BOP or other reagents (see March, J. Advanced Organic Chemistry, Fourth Edition 1992 John Wiley & Sons, New York). The resulting intermediate I-6 can be deprotected as described for intermediate I-1.

Some bicyclic heterocycles can be synthesized according to a variety of methods, some examples of which are illustrated in Scheme II. Using methods similar to that described in Sunderland, J. S.; Botta, M.; Aime, S.; Raymond, K. N. Inorg. Chem. 2001, 40, 6756-6756, II-1 and II-2 can be condensed to provide intermediate II-3. Intermediate II-3 can be reacted with thiourea to yield pyrimidinone II-4. Pyrimidinone II-4 can be transformed to II-5 by addition of an appropriately substituted ethylamine to the N-3 of the pyrimidinone. The sulfide of II-4 can be activated for nucleophilic displacement by treating with an appropriate oxidizing agent such as mCPBA to form the sulfone II-6. The sulfone can be displaced by the appropriately functionalized amino group to yield II-7. This compound can be carried on to the final product according to the methods described in Scheme I.

In Scheme III, the intermediate II-3 is prepared in the same manner as in Scheme II. Condensation with a cyclic guanidine, such as III-2 provides the bicyclic intermediate III-3, which in turn is carried on to final compound as described in Scheme I.

Biological Methods

Another aspect of the invention is a method for inhibiting HIV integrase comprising contacting a compound of Formula I with HIV integrase.

Another aspect of the invention is a method for inhibiting HIV viral cDNA integration into human DNA comprising administering an effective amount of a compound of Formula I to a human cell infected with HIV.

HIV-Integrase Inhibition Activity. To evaluate in-vitro activity against HIV-integrase, 5 pmole of biotin labeled substrate DNA was bound to 100 μg of Streptavidin coated PVT SPA beads (Amersham Pharmacia Biotech). Recombinant integrase (0.26 ng) was incubated with the beads for 90 min at 37° C. Unbound enzyme was removed by washing the complex followed by addition of inhibitors and 0.1 fmol of P33 labeled target DNA. The reaction was stopped by adding EDTA to a final concentration of 10 mM. Samples were counted in TopCountNXT (Packard) and the CPM was used as a measure of integration. The reaction condition was as described in A. Engelman and R. Craigie, J. Virol. 69, 5908-5911 (1995). The sequences of substrate and target DNA were described in Nucleic Acid Research 22,1121-1122 (1994). Results shown in the Table 1. Activity equal to A refers to a compound having IC₅₀=0.005 to 0.010 μM while B and C denote compounds having IC₅₀=0.010 to 0.030 μM and IC₅₀>0.030 μM respectively.

TABLE 1
Example Activity
1       B
2       B
3       B
4       B
5       B
6       B
7       B
8       A
9       B
10      C
11      A
12      B
13      B
14      B
15      A
16      C
17      B
18      B
19      B
20      A
21      A
22      B
23      A
24      A
25      B
26      B
27      B
28      A
29      B
30      B
31      B
32      A
33      A
34      A
35      B
36      B
37      B
38      C
39      C
40      A
41      B
42

Inhibition of HIV replication. A recombinant NL-Rluc virus was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. The NL-RLuc virus was prepared by co-transfection of two plasmids, pNLRLuc and pVSVenv. The pNLRLuc contains the NL-Rluc DNA cloned into pUC18 at the PvuII site, while the pVSVenv contains the gene for VSV G protein linked to an LTR promoter. Transfections were performed at a 1:3 ratio of pNLRLuc to pVSVenv on 293T cells using the LipofectAMINE PLUS kit from Invitrogen (Carlsbad, Calif.) according to manufactures instruction, and the pseudotype virus generated was titered in MT-2 cells.

Susceptibility of viruses to compounds was determined by incubation in the presence of serial dilutions of the compound. The 50% effective concentration (EC₅₀) was calculated by using the exponential form of the median effect equation where (Fa)=1/[1+(ED₅₀/drug conc.)^m] (Johnson V A, Byington R T. Infectivity Assay. In Techniques in HIV Research. ed. Aldovini A, Walker B D. 71-76. New York: Stockton Press. 1990). The anti-viral activity of compounds was evaluated under three serum conditions, 10% FBS, 15 mg/ml human serum albumin/10% FBS or 40% human serum/5% FBS, and the results from at least 2 experiments were used to calculate the EC₅₀ values. Results are shown in the Table 2. Activity equal to A refers to a compound having EC₅₀=0.004 to 0.030 μM while B and C denote compounds with EC₅₀=0.030 to 0.1 μM and EC₅₀>0.1 μM respectively.

TABLE 2
Example Activity
1       C
2       C
3       C
4       C
5       C
6       C
7       C
8       C
9       A
10      A
11      C
12      C
13      C
14      A
15      A
16      B
17      B
18      B
19      B
20      B
21      A
22      A
23      A
24      A
25      A
26      A
27      A
28      A
29      C
30      C
31      C
32      C
33      C
34      A
35      B
36      C
37      C
38      C

Pharmaceutical Composition and Methods of Use

The compounds of this invention inhibit HIV integrase. HIV integrase inhibitors belonging to a class of diketo acid compounds prevented viral integration and inhibited HIV-1 replication in cells (Hazuda et al. Science 2000, 287, 646). Recently, HIV integrase inhibitors have been accepted into clinical trials for treating AIDS and HIV infection (Neamati Expert. Opin. Ther. Patents 2002, 12, 709, Pais and Burke Drugs Fut. 2002, 27, 1101).

Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

Another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection. Some suitable agents are nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

Another aspect of the invention is a composition for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

“Combination,” “coadministration,” “concurrent,” and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly active antiretroviral therapy (HAART) as understood by practitioners in the field of AIDS and HIV infection.

“Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of treatment are suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

“Patient” means a person infected with the HIV virus and suitable for therapy as understood by practitioners in the field of AIDS and HIV infection.

“Treatment,” “therapy,” “regimen,” “HIV infection,” “ARC,” “AIDS” and related terms are used as understood by practitioners in the field of AIDS and HIV infection.

The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions.

Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred.

Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg.

Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.

Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.

The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating AIDS and HIV infection. Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-infectives. In these combination methods, the compound of Formula I will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

Table 3 lists some agents useful in treating AIDS and HIV infection which are suitable for this invention.

TABLE 3
DRUG NAME	MANUFACTURER	INDICATION
ANTIVIRALS
097	Hoechst/Bayer	HIV infection, AIDS,
(non-nucleoside reverse		ARC
transcriptase inhibitor)
Amprenavir	Glaxo Wellcome	HIV infection, AIDS,
141 W94		ARC
GW 141
(protease inhibitor)
Abacavir (1592U89)	Glaxo Wellcome	HIV infection, AIDS,
GW 1592		ARC
(RT inhibitor)
Acemannan	Carrington Labs	ARC
	(Irving, TX)
Acyclovir	Burroughs Wellcome	HIV infection, AIDS,
		ARC, in combination
		with AZT
AD-439	Tanox Biosystems	HIV infection, AIDS,
		ARC
AD-519	Tanox Biosystems	HIV infection, AIDS,
		ARC
Adefovir dipivoxil	Gilead Sciences	HIV infection, ARC,
AL-721	Ethigen	PGL HIV positive, AIDS
	(Los Angeles, CA)
Alpha Interferon	Glaxo Wellcome	Kaposi's sarcoma
HIV in combination
w/Retrovir
Ansamycin	Adria Laboratories	ARC
LM 427	(Dublin, OH)
	Erbamont
	(Stamford, CT)
Antibody which	Advanced Biotherapy	AIDS, ARC
Neutralizes pH	Concepts
Labile alpha aberrant	(Rockville, MD)
Interferon
AR177	Aronex Pharm	HIV infection, AIDS,
		ARC
Beta-fluoro-ddA	Nat'l Cancer Institute	AIDS-associated diseases
BMS-232623	Bristol-Myers Squibb/	HIV infection, AIDS,
(CGP-73547)	Novartis	ARC
(protease inhibitor)
BMS-234475	Bristol-Myers Squibb/	HIV infection, AIDS,
(CGP-61755)	Novartis	ARC
(protease inhibitor)
CI-1012	Warner-Lambert	HIV-1 infection
Cidofovir	Gilead Science	CMV retinitis, herpes,
		papillomavirus
Curdlan sulfate	AJI Pharma USA	HIV infection
Cytomegalovirus	MedImmune	CMV retinitis
Immune globin
Cytovene	Syntex	Sight threatening
Ganciclovir		CMV peripheral, CMV
		retinitis
Delaviridine	Pharmacia-Upjohn	HIV infection, AIDS,
(RT inhibitor)		ARC
Dextran Sulfate	Ueno Fine Chem.	AIDS, ARC, HIV
	Ind. Ltd. (Osaka,	positive asymptomatic
	Japan)
ddC	Hoffman-La Roche	HIV infection, AIDS,
Dideoxycytidine		ARC
ddI	Bristol-Myers Squibb	HIV infection, AIDS,
Dideoxyinosine		ARC; combinationwith
		AZT/d4T
DMP-450	AVID	HIV infection, AIDS,
(protease inhibitor)	(Camden, NJ)	ARC
Efavirenz	DuPont Merck	HIV infection, AIDS,
(DMP 266)		ARC
(−)6-Chloro-4-(S)-
cyclopropylethynyl-
4(S)-trifluoro-
methyl-1,4-dihydro-
2H-3,1-benzoxazin-
2-one, STOCRINE
(non-nucleoside RT
inhibitor)
EL10	Elan Corp, PLC	HIV infection
	(Gainesville, GA)
Famciclovir	Smith Kline	herpes zoster, herpes
		simplex
FTC	Emory University	HIV infection, AIDS,
(reverse transcriptase		ARC
inhibitor)
GS 840	Gilead	HIV infection, AIDS,
(reverse transcriptase		ARC
inhibitor)
HBY097	Hoechst Marion	HIV infection, AIDS,
(non-nucleoside reverse	Roussel	ARC
transcriptaseinhibitor)
Hypericin	VIMRx Pharm.	HIV infection, AIDS,
		ARC
Recombinant Human	Triton Biosciences	AIDS, Kaposi's sarcoma,
Interferon Beta	(Almeda, CA)	ARC
Interferon alfa-n3	Interferon Sciences	ARC, AIDS
Indinavir	Merck	HIV infection, AIDS,
		ARC, asymptomatic HIV
		positive, also in
		combination with
		AZT/ddI/ddC
ISIS 2922	ISIS Pharmaceuticals	CMV retinitis
KNI-272	Nat'l Cancer Institute	HIV-associated diseases
Lamivudine, 3TC	Glaxo Wellcome	HIV infection, AIDS,
(reverse transcriptase		ARC, also with AZT
inhibitor)
Lobucavir	Bristol-Myers Squibb	CMV infection
Nelfinavir	Agouron	HIV infection, AIDS,
(protease inhibitor)	Pharmaceuticals	ARC
Nevirapine	Boeheringer	HIV infection, AIDS,
(RT inhibitor)	Ingleheim	ARC
Novapren	Novaferon Labs, Inc.	HIV inhibitor
	(Akron, OH)
Peptide T	Peninsula Labs	AIDS
Octapeptide	(Belmont, CA)
Sequence
Trisodium	Astra Pharm.	CMV retinitis, HIV
Phosphonoformate	Products, Inc.	infection, other CMV
		infections
PNU-140690	Pharmacia Upjohn	HIV infection, AIDS,
(protease inhibitor)		ARC
Probucol	Vyrex	HIV infection, AIDS
RBC-CD4	Sheffield Med.	HIV infection, AIDS,
	Tech (Houston, TX)	ARC
Ritonavir	Abbott	HIV infection, AIDS,
(protease inhibitor)		ARC
Saquinavir	Hoffmann-	HIV infection, AIDS,
(protease inhibitor)	LaRoche	ARC
Stavudine; d4T	Bristol-Myers Squibb	HIV infection, AIDS,
Didehydrodeoxy-		ARC
thymidine
Valaciclovir	Glaxo Wellcome	Genital HSV &
		CMVinfections
Virazole	Viratek/ICN	asymptomatic HIV-
Ribavirin	(Costa Mesa, CA)	positive, LAS, ARC
VX-478	Vertex	HIV infection, AIDS,
		ARC
Zalcitabine	Hoffmann-LaRoche	HIV infection, AIDS,
		ARC, with AZT
Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS,
		ARC, Kaposi's sarcoma,
		in combination with other therapies
Tenofovir disoproxil,	Gilead	HIV infection, AIDS
fumarate salt (Viread ®)
(reverse transcriptase
inhibitor)
Combivir ®	GSK	HIV infection, AIDS
(reverse transcriptase
inhibitor)
abacavir succinate	GSK	HIV infection, AIDS
(or Ziagen ®)
(reverse transcriptase
inhibitor)
Reyataz ®	Bristol-Myers Squibb	HIV infection, AIDS
(atazanavir)
Fuzeon	Roche/Trimeris	HIV infection, AIDS,
(Enfuvirtide, T-20)		viral fusion inhibitor
Trizivir ®		HIV infection, AIDS
Kaletra ®	Abbott	ARC
IMMUNOMODULATORS
AS-101	Wyeth-Ayerst	AIDS
Bropirimine	Pharmacia Upjohn	Advanced AIDS
Acemannan	Carrington Labs, Inc.	AIDS, ARC
	(Irving, TX)
CL246,738	American Cyanamid	AIDS, Kaposi's sarcoma
	Lederle Labs
EL10	Elan Corp, PLC	HIV infection
	(Gainesville, GA)
FP-21399	Fuki ImmunoPharm	Blocks HIV fusion with
		CD4+ cells
Gamma Interferon	Genentech	ARC, in combination
		w/TNF (tumor necrosis
		factor)
Granulocyte	Genetics Institute	AIDS
Macrophage Colony	Sandoz
Stimulating Factor
Granulocyte	Hoechst-Roussel	AIDS
Macrophage Colony	Immunex
Stimulating Factor
Granulocyte	Schering-Plough	AIDS, combination
Macrophage Colony		w/AZT
Stimulating Factor
HIV Core Particle	Rorer	Seropositive HIV
Immunostimulant
IL-2	Cetus	AIDS, in combination
Interleukin-2		w/AZT
IL-2	Hoffman-LaRoche	AIDS, ARC, HIV, in
Interleukin-2	Immunex	combination w/AZT
IL-2	Chiron	AIDS, increase in CD4
Interleukin-2		cell counts
(aldeslukin)
Immune Globulin	Cutter Biological	Pediatric AIDS, in
Intravenous	(Berkeley, CA)	combination w/AZT
(human)
IMREG-1	Imreg	AIDS, Kaposi's sarcoma,
	(New Orleans, LA)	ARC, PGL
IMREG-2	Imreg	AIDS, Kaposi's sarcoma,
	(New Orleans, LA)	ARC, PGL
Imuthiol Diethyl	Merieux Institute	AIDS, ARC
Dithio Carbamate
Alpha-2	Schering Plough	Kaposi's sarcoma
Interferon		w/AZT, AIDS
Methionine-	TNI Pharmaceutical	AIDS, ARC
Enkephalin	(Chicago, IL)
MTP-PE	Ciba-Geigy Corp.	Kaposi's sarcoma AIDS,
Muramyl-Tripeptide	Amgen	in combination w/AZT
Granulocyte
Colony Stimulating
Factor
Remune	Immune Response	Immunotherapeutic
	Corp.
rCD4	Genentech	AIDS, ARC
Recombinant
Soluble Human CD4
rCD4-IgG		AIDS, ARC
hybrids
Recombinant	Biogen	AIDS, ARC
Soluble Human CD4
Interferon	Hoffman-La Roche	Kaposi's sarcoma, AIDS,
Alfa 2a	in combination w/AZT	ARC
SK&F106528	Smith Kline	HIV infection
Soluble T4
Thymopentin	Immunobiology	HIV infection
	Research Institute
	(Annandale, NJ)
Tumor Necrosis	Genentech	ARC, in combination
Factor; TNF		w/gamma Interferon
ANTI-INFECTIVES
Clindamycin with	Pharmacia Upjohn	PCP
Primaquine
Fluconazole	Pfizer	Cryptococcal meningitis,
		candidiasis
Pastille	Squibb Corp.	Prevention of oral
Nystatin Pastille		candidiasis
Ornidyl	Merrell Dow	PCP
Eflornithine
Pentamidine	LyphoMed	PCP treatment
Isethionate (IM & IV)	(Rosemont, IL)
Trimethoprim		Antibacterial
Trimethoprim/sulfa		Antibacterial
Piritrexim	Burroughs Wellcome	PCP treatment
Pentamidine	Fisons Corporation	PCP prophylaxis
Isethionate for
Inhalation
Spiramycin	Rhone-Poulenc	Cryptosporidial
	diarrhea
Intraconazole-	Janssen-Pharm.	Histoplasmosis;
R51211		cryptococcal meningitis
Trimetrexate	Warner-Lambert	PCP
Daunorubicin	NeXstar, Sequus	Kaposi's sarcoma
Recombinant Human	Ortho Pharm. Corp.	Severe anemia assoc.
Erythropoietin		with AZT therapy
Recombinant Human Growth	Serono	AIDS-related wasting,
Hormone		cachexia
Megestrol Acetate	Bristol-Myers Squibb	Treatment of anorexia
		assoc. W/AIDS
Testosterone	Alza, Smith Kline	AIDS-related wasting
Total Enteral	Norwich Eaton	Diarrhea and
Nutrition	Pharmaceuticals	malabsorption related to
		AIDS

DESCRIPTION OF SPECIFIC EMBODIMENTS

Ethyl 6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Diethyl oxalate (7.66 g, 52.4 mmol) and ethyl benzyloxyacetate (10.2 g, 52.5 mmol) in dry tetrahydrofuran (70 ml) were treated at 22° C. with sodium hydride (2.31 g of a 60% dispersion in mineral oil, 57.7 mmol). Ethanol (40 μl) was then added and the mixture was stirred under argon for 16 h. The tetrahydrofuran was then concentrated under reduced pressure and the residue was treated with a mixture of 1-methyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide (9.45 g, 52.5 mmol) (J. V. Grennhill et al. J. Chem. Soc. Perkin Trans.II, 1985, 1255-1264) in a solution of sodium ethoxide (26.0 mmol, prepared from 0.60 g of sodium) in ethanol (70 ml) and the resulting mixture was heated at 60° C. for 3 h. Acetic acid (2 ml) was added and the ethanol was evaporated under reduced pressure. The residue was diluted with ethyl acetate washed successively with saturated sodium bicarbonate and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Chromatography on silica gel (elution gradient of ethanol 0-20% in ethyl acetate) gave 5.33 g (30% yield) of intermediate 1 as white crystals; mp 135-137° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.32 (3H, t, J=7.1 Hz, CH₃), 3.03 (3H, s, NCH₃), 3.71 (2H, t, J=9.1 Hz, CH₂), 4.15 (2H, t, J=9.1 Hz, CH₂), 4.33 (2H, q, J=7.1 Hz, OCH₂), 5.10 (2H, s, OCH₂), 7.3-7.51 (5H, m, aromatics). Anal. Calcd for C₁₇H₁₉N₃O₄: C 61.99, H 5.81, N 12.75; Found: C 61.73, H 5.78, N 12.73.

6-(Benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. A solution of ethyl 6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (0.971 g, 2.95 mmol) in a mixture tetrahydrofuran (20 ml) and ethanol (20 ml) was treated with 15 ml of 1 N sodium hydroxide and the mixture was stirred at 40° C. for 30 min. The solvent was then concentrated under reduced pressure and the residue was acidified with 1 N hydrochloric acid (20 ml). The precipitate formed was filtered, washed with water and dried in vacuo to give 0.874 g (98% yield) of the title acid as a white solid; mp 203° C. (dec; ethyl acetate). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.87 (3H, s, NCH₃), 3.66 (2H, t, J=9 Hz, CH₂), 4.01 (2H, t, J=9 Hz, CH₂), 4.91 (2H, s, OCH₂), 7.3-7.45 (5H, m, aromatics). HRMS (ESI⁺) calculated for C₁₅H₁₆N₃O₄ [M+H⁺]: 302.1141; found: 302.1127.

N-(4-Fluorobenzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. A mixture of 6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.393 g, 1.30 mmol) and 4-fluorobenzylamine (0.163 g, 1.30 mmol) in acetonitrile (15 ml) was treated at 25° C. with triethylamine (0.42 ml, 2.5 mmol) followed by benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate (0.662 g, 1.49 mmol). After 3 h, the reaction mixture was diluted with ethyl acetate, washed successively with 0.1 N hydrochloric acid, saturated sodium bicarbonate and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Crystallization of the residual solid from ethyl acetate gave 0.407 g (76% yield) of the title amide as white cubes; mp 189-191° C. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.02 (3H, s, NCH₃), 3.70 (2H, t, J=9 Hz, CH₂), 4.15 (2H, t, J=9 Hz, CH₂), 4.50 (2H, d, J=5.6 Hz, NCH₂), 5.11 (2H, s, OCH₂), 7.0 (2H, m, aromatics), 7.24 (2H, m, aromatics), 7.3-7.45 (SH, m, aromatics), 7.71 (1H, broad t, NH). Anal. Calcd for C₂₂H₂₁FN₄O₃: C 64.69, H 5.18, N 13.71; Found: C 64.41, H 5.10, N 13.72.

EXAMPLE 1

N-(4Fluorobenzyl)-6-hydroxy-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. A solution of N-(4-fluorobenzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.202 g, 0.495 mmol) in a mixture of ethyl acetate (150 ml) and ethanol (20 ml) at 25° C. was hydrogenated over 10% palladium on activated carbon (50 mg) and under one atmosphere of hydrogen for one hour to give 0.130 g (83% yield) of the title compound as white needles; mp 212° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.93 (3H, s, CH₃), 3.63 (2H, t, J=8.6 Hz, CH₂), 4.14 (2H, t, J=8.6 Hz, CH₂), 4.59 (2H, d, J=6.0 Hz, NCH₂), 7.07 (2H, m, aromatics), 7.33 (2H, m, aromatics), 7.89 (1H, broad t, NH), 11.57 (1H, s, OH). HRMS (ESI⁺) calculated for C₁₅H₁₆FN₄O₃ [M+H⁺]: 319.1206; found: 319.1191.

N-(4-Fluoro-3-methylbenzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydromidazo[1,2-a]pyrimidine-7-carboxylic acid (0.439 g, 1.46 mmol) and 4-fluoro-3-methylbenzylamine (0.203 g, 1.46 mmol) as described for the synthesis of intermediate 3 gave 0.372 g (60% yield) of the title amide as white crystals; mp 182-184° C. (ethyl acetate). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.12 (3H, s, CH₃), 2.90 (3H, s, NCH₃), 3.66 (2H, t, J=8.6 Hz, CH₂), 4.02 (2H, t, J=8.6 Hz, CH₂), 4.33 (2H, d, J=6.0 Hz, NCH₂), 4.88 (2H, s, OCH₂), 6.97 (1H, m, aromatic), 7.11-7.2 (2H, m, aromatics), 7.3-7.4 (5H, m, aromatics), 8.81 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₃H₂₄FN₄O₃ [M+H⁺]: 423.1832; found: 423.1827.

EXAMPLE 2

N-(4-Fluoro-3-methylbenzyl)-6-hydroxy-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluoro-3-methylbenzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.338 g, 0.80 mmol) as described for example 1 gave 0.191 g (72% yield) of the title compound as white crystals; mp 187-189° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.30 (3H, s, CH₃), 2.93 (3H, s, CH₃), 3.63 (2H, t, J=8.6 Hz, CH₂), 4.14 (2H, t, J=8.6 Hz, CH₂), 4.54 (2H, d, J=6.2 Hz, NCH₂), 7.0 (1H, m, aromatic), 7.12-7.18 (2H, m, aromatics), 7.87 (1H, broad t, NH), 11.59 (1H, s, OH). Anal. Calcd for C₁₆H₁₇FN₄O₃: C 57.82, H 5.15, N 16.85; Found: C 57.51, H 5.27, N 16.69.

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 1.0 mmol) and 2-(aminomethyl)-5-fluoro-N-methylbenzamide trifluoroacetate salt (0.295 g, 1.0 mmol) as described for the synthesis of intermediate 3 gave 0.253 g (54% yield) of the title amide as white crystals; mp 184° C. (ethyl acetate-hexane). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.78 (3H, d, J=4.5 Hz, NCH₃), 2.91 (3H, s, NCH₃), 3.66 (2H, t, J=8.9 Hz, CH₂), 4.02 (2H, t, J=8.9 Hz, CH₂), 4.46 (2H, d, J=6.2 Hz, NCH₂), 4.90 (2H, s, OCH₂), 7.04 (1H, m, aromatic), 7.25 (1H,dd, J=2.6 Hz and J=9.1 Hz, aromatic), 7.29-7.46 (6H, m, aromatics), 8.49 (1H, broad q, NH), 8.78 (l H, broad t, NH). HRMS (ESI⁺) calculated for C₂₄H₂₅FN₅O₄ [M+H⁺]: 466.1891; found: 466.1899.

EXAMPLE 3

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-hydroxy-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-1-methyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.223 g, 0.48 mmol) as described for example 1 gave 0.048 g (27% yield) of the title compound a white solid. ¹HNMR 400 MHz (CDCl₃) δ (ppm): ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.80 (3H, d, J=4.5 Hz, CH₃), 2.89 (3H, s, NCH₃), 3.56 (2H, t, J=8.6 Hz, CH₂), 3.97 (2H, t, J=8.6 Hz, CH₂), 4.53 (2H, d, J=6.5 Hz, NCH₂), 7.27-7.4 (3H, m, aromatics), 8.54 (1H, broad q, NH), 9.18 (1H, broad t, NH), 11.60 (1H, s, OH). HRMS (ESI⁺) calculated for C₁₇H₁₉FN₅O₄ [M+H⁺]: 376.1421; found: 376.1410.

1-Isopropyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide. A solution of N-isopropylethylenediamine (10.0 g, 0.097 mol) in methanol (10 ml) was cooled to 0° C. and treated dropwise with a solution of cyanogen bromide (10.37 g, 0.098 mol) in methanol (25 ml) while maintaining the temperature below 10° C. The reaction mixture was then heated to 80° C. for 45 min, cooled and concentrated under reduced pressure. Crystallization of the residue from cold ethanol gave 10.4 g (50% yield) of the title product as white crystals; mp 154-155° C. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.27 (6H, d, J=6.6 Hz, 2×CH₃), 3.57-3.75 (4H, m, 2×CH₂), 4.41 (1H, m, CH).

Ethyl 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (7.26 g, 49.7 mmol), ethyl benzyloxyacetate (9.65 g, 49.7 mmol) and sodium hydride (2.19 g of a 60% dispersion in mineral oil, 54.7 mmol) with 1-isopropyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide (10.33 g, 49.7 mmol) as described for intermediate 1 gave 6.79 g (38% yield) of the title ester as white crystals; mp 131-132° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.22 (6H, d, J=6.8 Hz, 2×CH₃), 1.31 (3H, t, J=7.1 Hz, CH₃), 3.66 (2H, t, J=9 Hz, CH₂), 4.13 (2H, t, J=9 Hz, CH₂), 4.31 (2H, q, J=7.1 Hz, OCH₂), 4.40 (1H, m, CH), 5.08 (2H, s, OCH₂), 7.3-7.39 (3H, m, aromatics), 7.49 (2H, m, aromatics). Anal. Calcd for C₁₉H₂₃N₃O₄: C 63.85, H 6.48, N 11.75; Found: C 63.57, H 6.76, N 11.98.

6-(Benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. Saponification of ethyl 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (2.00 g, 5.60 mmol) as described for intermediate 2 gave 1.84 g (100% yield) of the title acid as a white solid; mp 163-165° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.7 Hz, 2×CH₃), 3.67 (2H, t, J=9 Hz, CH₂), 4.14 (2H, t, J=9 Hz, CH₂), 4.34 (1H, m, CH), 5.23 (2H, s, OCH₂), 7.3-7.39 (3H, m, aromatics), 7.57 (2H, m, aromatics). HRMS (ESI⁺) calculated for C₁₇H₂₀N₃O₄ [M+H⁺]: 330.1454; found: 330.1458.

N-(4-Fluorobenzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 0.91 mmol) and 4-fluorobenzylamine (0.120 g, 0.96 mmol) as described for the synthesis of intermediate 3 gave 0.385 g (96% yield) of the title amide as white crystals; mp 166-167° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.8 Hz, 2×CH₃), 3.67 (2H, t, J=9 Hz, CH₂), 4.14 (2H, t, J=9 Hz, CH₂), 4.42 (1H, m, CH), 4.50 (2H, d, J=6.0 Hz, NCH₂), 5.09 (2H, s, OCH₂), 7.0 (2H, m, aromatics), 7.25 (2H, m, aromatics), 7.3-7.37 (3H, m, aromatics), 7.46 (2H, m, aromatics), 7.69 (1H, broad t, NH). Anal. Calcd for C₂₄H₂₅FN₄O₃: C 66.04, H 5.77, N 12.83; Found: C 65.84, H 5.85, N 12.58.

EXAMPLE 4

N-(4-Fluorobenzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluorobenzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.200 g, 0.46 mmol) as described for example 1 gave 0.134 g (84% yield) of the title compound as a white solid. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.21 (6H, d, J=6.8 Hz, 2×CH₃), 3.60 (2H, t, J=8.6 Hz, CH₂), 4.13 (2H, t, J=8.6 Hz, CH₂), 4.22 (1H, m, CH), 4.59 (2H, d, J=6.3 Hz, NCH₂), 7.07 (2H, m, aromatics), 7.33 (2H, m, aromatics), 7.88 (1H, broad t, NH),11.51 (1H, broad, OH). HRMS (ESI⁺) calculated for C₁₇H₂₀FN₄O₃ [M+H⁺]: 347.1519; found: 347.1520.

N-(4-Fluoro-3-methylbenzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy) 1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 0.91 mmol) and 4-fluoro-3-methylbenzylamine (0.133 g, 0.95 mmol) as described for the synthesis of intermediate 3 gave 0.384 g (93% yield) of the title amide as white crystals (ethyl acetate-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.6 Hz, 2×CH₃), 2.25 (3H, broad d, J=1.8 Hz, CH₃), 3.67 (2H, t, J=9 Hz, CH₂), 4.13 (2H, t, J=9 Hz, CH₂), 4.41 (1H, m, CH), 4.46 (2H, d, J=5.8 Hz, NCH₂), 5.08 (2H, s, OCH₂), 6.94 (1H, m, aromatic), 7.04-7.08 (1H, m, aromatic), 7.11 (1H, m, aromatic), 7.3-7.36 (3H, m, aromatics), 7.42-7.46 (2H, m, aromatics), 7.69 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₅H₂₈FN₄O₃ [M+H⁺]: 451.2145; found: 451.2141.

EXAMPLE 5

N-(4-Fluoro-3-methylbenzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluoro-3-methylbenzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.200 g, 0.44 mmol) as described for example 1 gave 0.130 g (81 % yield) of the title compound a white solid. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.21 (6H, d, J=6.8 Hz, 2×CH₃), 2.29 (3H, d, J=1.7 Hz, CH₃), 3.60 (2H, t, J=8.5 Hz, CH₂), 4.13 (2H, t, J=8.5 Hz, CH₂), 4.22 (1H, m, CH), 4.55 (2H, d, J=6.4 Hz, NCH₂), 7.0 (1H, m, aromatic), 7.15 (2H, m, aromatics), 7.86 (1H, broad t, NH), 11.54 (1H, broad, OH). HRMS (ESI⁺) calculated for C₁₈H₂₂FN₄O₃ [M+H⁺]: 361.1676; found: 361.1691.

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 0.91 mmol) and 2-(aminomethyl)-5-fluoro-N-methylbenzamide trifluoroacetate salt (0.210 g, 0.96 mmol) as described for the synthesis of intermediate 3 gave 0.328 g (72% yield) of the title amide as white crystals; mp 197-198° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.8 Hz, 2×CH₃), 2.98 (3H, d, J=5 Hz, NCH₃), 3.66 (2H, t, J=9 Hz, CH₂), 4.12 (2H, t, J=9 Hz, CH₂), 4.43 (1H, m, CH), 4.48 (2H, d, J=6.3 Hz, NCH₂), 5.09 (2H, s, OCH₂), 7.05 (1H, m, aromatic), 7.13-7.17 (2H, m, aromatics), 7.3-7.35 (4H, m, NH and aromatics), 7.43-7.46 (2H, m, aromatics), 8.35 (1H, broad t, NH). Anal. Calcd for C₂₆H₂₈FN₅O₄: C 63.27, H 5.71, N 14.19; Found: C 63.06, H 5.65, N 14.02.

EXAMPLE 6

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.200 g, 0.40 mmol) as described for example 1 gave 0.125 g (77% yield) of the title compound white crystals; mp 205° C. (dec) (dichloromethane-ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.24 (6H, d, J=6.6 Hz, 2×CH₃), 3.04 (3H, d, J=5.0 Hz, NCH₃), 3.59 (2H, t, J=8.5 Hz, CH₂),4.09 (2H, t, J=8.5 Hz, CH₂),4.31 (1H, m, CH), 4.61 (2H, d, J=6.6 Hz, NCH₂), 6.42 (1H, broad, NH), 7.10-7.20 (2H, m, aromatics), 7.49 (1H, dd, J=5.5 Hz and J=8.5 Hz, aromatic), 8.65 (1H, broad t, NH), 11.45 (1H, broad, OH). Anal. Calcd for C₁₉H₂₂FN₅O₄: C 56.57, H 5.49, N 17.36; Found: C 56.34, H 5.24, N 17.26.

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 0.91 mmol) and (4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl)methanamine hydrochloride (0.210 g, 0.96 mmol) as described for the synthesis of intermediate 3 gave 0.349 g (76% yield) of the title amide as white crystals; mp 171-172° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.24 (6H, d, J=6.8 Hz, 2×CH₃), 3.66 (2H, t, J=9 Hz, CH₂), 4.13 (2H, t, J=9 Hz, CH₂), 4.41 (2H, d, J=6.3 Hz, NCH₂), 4.43 (1H, m, CH), 5.10 (2H, s, OCH₂), 7.06 (1H, dd, J=2.6 Hz and J=8.6 Hz, aromatic), 7.17 (1H, m, aromatic), 7.29-7.31 (3H, m, aromatics), 7.45-7.48 (2H, m, aromatics), 7.71 (1H, dd, J=5.9 Hz and J=8.6 Hz, aromatic), 8.0 (1H, s, CH), 8.36 (1H, broad t, NH), 8.39 (1H, s, CH). Anal. Calcd for C₂₆H₂₆FN₇O₃: C 62.01, H 5.20, N 19.47; Found: C 62.00, H 5.20, N 19.50.

EXAMPLE 7

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.200 g, 0.40 mmol) as described for example 1 gave 0.134 g (82% yield) of the title compound white crystals (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.27 (6H, d, J=6.5 Hz, 2×CH₃), 3.60 (2H, t, J=8.5 Hz, CH₂), 4.12 (2H, t, J=8.5 Hz, CH₂), 4.25 (1H, m, CH), 4.48 (2H, d, J=6.8 Hz, NCH₂), 7.13 (1H, dd, J=2.5 Hz and J=8.4 Hz, aromatic), 7.24 (1H, m, aromatic), 7.69 (1H, dd, J=5.8 Hz and J=8.6 Hz, aromatic), 8.18 (1H, s, CH), 8.46 (1H, s, CH), 8.66 (1H, broad t, NH), 11.41 (1H, broad, OH). HRMS (ESI⁺) calculated for C₁₉H₂₁FN₇O₃ [M+H⁺]: 414.1690; found: 414.1677.

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-benzyloxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.150 g, 0.45 mmol) and 4-fluoro-2-(N,N-dimethylsulfamoyl)benzylamine hydrochloride (0.147 g, 0.55 mmol) as described for the synthesis of intermediate 3 gave 0.190 g (75% yield) of the title amide as white crystals; mp 161-163° C. (ethyl acetate-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.9 Hz, 2×CH₃), 2.85 (6H, s, 2×NCH₃), 3.65 (2H, t, J=9 Hz, CH₂),4.12 (2H, t, J=9 Hz, CH₂),4.40 (1H, m, CH), 4.81 (2H, d, J=6.6 Hz, NCH₂), 5.13 (2H, s, OCH₂), 7.22 (1H, m, aromatic), 7.28-7.34 (3H, m, aromatics), 7.49-7.52 (2H, m, aromatics), 7.55 (1H, dd, J=2.6 Hz and J=8.6 Hz, aromatic), 7.71 (1H, dd, J=5.6 Hz and J=8.6 Hz, aromatic), 8.26 (1H, broad t, NH). Anal. Calcd for C₂₆H₃₀FN₅O₅S: C 57.44, H 5.56, N 12.88; Found: C 57.40, H 5.46, N 12.85.

EXAMPLE 8

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. A solution of N-(4-fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-benzyloxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.155 g, 0.28 mmol) in trifluoroacetic acid (10 ml) was stirred at 25° C. for 72 h. The solvent was then evaporated under reduced pressure and the residue was purified by preparative HPLC (column YMC Pack C-18, 5μ, 20×250 mm, elution gradient acetonitrile-water 0.1% trifluoroacetic acid) to give 0.105 g (81% yield) of the title amide as a white solid.

¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.6 Hz, 2×CH₃), 2.91 (6H, s, 2×NCH₃), 3.59 (2H, t, J=8.5 Hz, CH₂), 4.11 (2H, t, J=8.5 Hz, CH₂), 4.24 (1H, m, CH), 4.84 (2H, d, J=6.8 Hz, NCH₂), 7.30 (1H, m, aromatic), 7.56 (1H, dd, J=2.8 Hz and J=8.3 Hz, aromatic), 7.70 (1H, dd, J=5.3 Hz and J=8.6 Hz, aromatic), 8.52 (1H, broad t, NH), 11.4 (1H, broad, OH). MS (ESI⁺) m/e 454 [M+H⁺].

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate-hexane). (75% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.23 (6H, d, J=6.9 Hz, 2×CH₃), 2.46 (3H, s,CH₃), 3.66 (2H, t, J=8.9 Hz, CH₂), 4.13 (2H, t, J=8.9 Hz, CH₂), 4.43 (1H, m, CH), 4.44 (2H, d, J=6.3 Hz, NCH₂), 5.10 (2H, s, OCH₂), 7.05 (1H, dd, J=2.7 Hz and J=8.6 Hz, aromatic), 7.14 (1H, m, aromatic), 7.27-7.28 (3H, m, aromatics), 7.42-7.45 (2H, m, aromatics), 7.69 (1H, dd, J=6.1 Hz and J=8.6 Hz, aromatic), 8.26 (1H, broad t, NH), 8.26 (1H, s, CH). MS (ESI⁺) m/e 518 [M+H⁺].

EXAMPLE 9

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (100% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.24 (6H, d, J=6.6 Hz, 2×CH₃), 2.55 (3H, s, CH₃), 3.60 (2H, t, J=8.5 Hz, CH₂), 4.12 (2H, t, J=8.5 Hz, CH₂), 4.31 (1H, m, CH), 4.49 (2H, d, J=6.6 Hz, NCH₂), 7.10 (1H, dd, J=2.5 Hz and J=8.3 Hz, aromatic), 7.20 (1H, m, aromatic), 7.70 (1H, dd, J=6.0 Hz and J=8.7 Hz, aromatic), 8.35 (1H, s, CH), 8.61 (1H, broad t, NH), 11.56 (1H, s, OH). MS (ESI⁺) m/e 428 [M+H⁺].

N-(4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 158-159° C. (ethyl acetate). (71% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.24 (6H, d, J=6.5 Hz, 2×CH₃), 2.44 (3H, s, CH₃), 3.66 (2H, t, J=8.8 Hz, CH₂), 4.13 (2H, t, J=8.8 Hz, CH₂), 4.23 (2H, d, J=6.3 Hz, NCH₂), 4.44 (1H, m, CH), 5.11 (2H, s, OCH₂), 6.99 (1H, dd, J=2.5 Hz and J=8.3 Hz, aromatic), 7.18 (1H, m, aromatic), 7.29-7.34 (3H, m, aromatics), 7.48-7.50 (2H, m, aromatics), 7.66 (1H, dd, J=6.0 Hz and J=8.7 Hz, aromatic), 7.89 (1H, s, CH), 8.10 (1H, broad t, NH). MS (ESI⁺) m/e 518 [M+H⁺].

EXAMPLE 10

N-(4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-1-isopropyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 212° C. (ethyl acetate). (61% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.27 (6H, d, J=6.8 Hz, 2×CH₃), 2.47 (3H, s, CH₃), 3.60 (2H, t, J=8.6 Hz, CH₂), 4.11 (2H, t, J=8.6 Hz, CH₂), 4.28 (1H, m, CH), 4.31 (2H, d, J=6.5 Hz, NCH₂), 7.03 (1H, dd, J=2.8 Hz and J=8.3 Hz, aromatic), 7.26 (1H, m, aromatic), 7.67 (1H, dd, J=6.0 Hz and J=8.6 Hz, aromatic), 8.00 (1H, s, CH), 8.35 (1H, broad t, NH), 11.35 (1H, s, OH). MS (ESI⁺) m/e 428 [M+H⁺].

1-Butyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide. Reaction of N-butylethylenediamine (10.7 g, 0.092 mol) with cyanogen bromide (9.76 g, 0.092 mol) as described in the preparation of intermediate 6 gave 11.77 g (57% yield) of the title compound as white crystals (ether-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.96 (3H, t, J=7.2 Hz, CH₃), 1.41 (2H, m, CH₂), 1.60 (2H, m, CH₂), 3.52 (2H, t, J=7.3 Hz, CH₂), 3.64-3.74 (4H, m, 2×CH₂), 7.58 and 7.7 (broad s, NH). MS (ESI⁺) m/e 142 [M+H⁺].

Ethyl 6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (5.71 g, 39.1 mmol), ethyl benzyloxyacetate (7.59 g, 39.1 mmol) and sodium hydride (1.71 g of a 60% dispersion in mineral oil, 42.7 nmnol) with 1-butyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide (8.68 g, 39.1 mmol) as described for intermediate 1 gave 5.55 g (38% yield) of the title ester as a clear oil. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.98 (3H, t, J=7.5 Hz, CH₃), 1.31 (3H, t, J=7.1 Hz, CH₃), 1.39 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 3.41 (2H, t, J=7.4 Hz, CH₂), 3.69 (2H, t, J=8.9 Hz, CH₂), 4.12 (2H, t, J=8.9 Hz, CH₂), 4.32 (2H, q, J=7.1 Hz, OCH₂), 5.09 (2H, s, OCH₂), 7.3-7.4 (3H, m, aromatics), 7.49 (2H, m, aromatics). MS (ESI⁺) m/e 372 [M+H⁺].

6-(Benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. Saponification of ethyl 6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (5.50 g, 14.8 mmol) as described for intermediate 2 gave 5.08 g (100% yield) of the title acid as a white solid; mp 132-135° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.98 (3H, t, J=7.3 Hz, CH₃), 1.34-1.44 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 3.39 (2H, t, J=7.4 Hz, CH₂), 3.71 (2H, t, J=8.9 Hz, CH₂), 4.15 (2H, t, J=8.9 Hz, CH₂), 5.23 (2H, s, OCH₂), 7.3-7.4 (3H, m, aromatics), 7.58 (2H, m, aromatics). MS (ESI⁺) m/e 344 [M+H⁺].

N-(4-Fluorobenzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Coupling of 6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid (0.300 g, 0.87 mmol) and 4-fluorobenzylamine (0.120 g, 0.96 mmol) as described for the synthesis of intermediate 3 gave 0.349 g (88% yield) of the title amide as white crystals; mp 107-109° C. (ethyl acetate-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.96 (3H, t, J=7.3 Hz, CH₃), 1.33-1.43 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 3.41 (2H, t, J=7.4 Hz, CH₂), 3.70 (2H, t, J=8.9 Hz, CH₂), 4.13 (2H, t, J=8.9 Hz, CH₂), 4.50 (2H, d, J=5.8 Hz, NCH₂), 5.10 (2H, s, OCH₂), 7.0 (2H, m, aromatics), 7.25 (2H, m, aromatics), 7.33-7.37 (3H, m, aromatics), 7.46-7.48 (2H, m, aromatics), 7.68 (1H, broad t, NH). MS (ESI⁺) m/e 451 [M+H⁺].

EXAMPLE 11

N-(4-Fluorobenzyl)-1-butyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. Hydrogenolysis of N-(4-fluorobenzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide (0.350 g, 0.77 mmol) as described for example 1 gave 0.278 g (99% yield) of the title compound as a white solid. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.95 (3H, t, J=7.3 Hz, CH₃), 1.33-1.42 (2H, m, CH₂),1.54-1.67 (2H, m, CH₂), 3.31 (2H, t, J=7.2 Hz, CH₂), 3.63 (2H, t, J=8.9 Hz, CH₂),4.14 (2H, t, J=8.9 Hz, CH₂), 4.59 (2H, d, J=6.3 Hz, NCH₂), 7.07 (2H, m, aromatics), 7.33 (2H, m, aromatics), 7.86 (1H, broad t, NH), 11.52 (1H, s, OH). MS (ESI⁺) m/e 361 [M+H⁺].

N-(4-Fluoro-3-methylbenzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid, (90% yield).

¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.96 (3H, t, J=7.3 Hz, CH₃), 1.35-1.43 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 2.25 (3H, d, J=1.8 Hz, CH₃), 3.41 (2H, t, J=7.5 Hz, CH₂), 3.70 (2H, t, J=8.9 Hz, CH₂), 4.15 (2H, t, J=8.9 Hz, CH₂), 4.46 (2H, d, J=5.8 Hz, NCH₂), 5.09 (2H, s, OCH₂), 6.94 (1H, m, aromatic), 7.04-7.07 (1H, m, aromatic), 7.10 (1H, d, J=7.2 Hz, aromatic), 7.30-7.36 (3H, m, aromatics), 7.44-7.47 (2H, m, aromatics), 7.67 (1H, broad t, NH). MS (ESI⁺) m/e 465 [M+H⁺].

EXAMPLE 12

N-(4-Fluoro-3-methylbenzyl)-1-butyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (94% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.95 (3H, t, J=7.3 Hz, CH₃), 1.28-1.42 (2H, m, CH₂), 1.54-1.63 (2H, m, CH₂), 2.29 (3H, d, J=1.8 Hz, CH₃), 3.31 (2H, t, J=7.3 Hz, CH₂), 3.63 (2H, t, J=8.9 Hz, CH₂), 4.14 (2H, t, J=8.9 Hz, CH₂), 4.54 (2H, d, J=6.4 Hz, NCH₂), 7.0 (1H, m, aromatic), 7.11-7.17 (2H, m, aromatics), 7.84 (1H, broad t, NH), 11.55 (1H, s, OH). MS (ESI⁺) m/e 375 [M+H⁺].

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid, (87% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.97 (3H, t, J=7.3 Hz, CH₃), 1.37-1.44 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 2.98 (3H, d, J=4.8 Hz, CH₃), 3.42 (2H, t, J=7.4 Hz, CH₂), 3.68 (2H, t, J=8.7 Hz, CH₂), 4.12 (2H, t, J=8.7 Hz, CH₂), 4.48 (2H, d, J=6.3 Hz, NCH₂), 5.10 (2H, s, OCH₂), 7.02-7.09 (2H, m, aromatic and NH), 7.14 (1H, dd, J=2.8 Hz and J=8.9 Hz, aromatic), 7.30-7.37 (4H, m, aromatics), 7.44-7.49 (2H, m, aromatics), 8.42 (1H, broad t, NH). MS (ESI⁺) m/e 508 [M+H⁺].

EXAMPLE 13

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-1-butyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 175-177° C. (ethyl acetate). (92% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.99 (3H, t, J=7.3 Hz, CH₃), 1.40-1.45 (2H, m, CH₂), 1.58-1.64 (2H, m, CH₂), 3.03 (3H, d, J=5.0 Hz, CH₃), 3.38 (2H, t, J=7.4 Hz, CH₂), 3.61 (2H, t, J=8.5 Hz, CH₂), 4.10 (2H, t, J=8.5 Hz, CH₂), 4.59 (2H, d, J=6.5 Hz, NCH₂), 6.40 (1H, broad q, NH), 7.11-7.15 (1H, m, aromatic), 7.18 (1H, dd, J=2.7 Hz and J=8.8 Hz, aromatic), 7.48 (1H, dd, J=5.4 Hz and J=8.5 Hz, aromatic), 8.81 (1H, broad t, NH), 11.48 (1H, s, OH). MS (ESI⁺) m/e 418 [M+H⁺].

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid, (95% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.96 (3H, t, J=7.3 Hz, CH₃), 1.34-1.44 (2H, m, CH₂), 1.55-1.66 (2H, m, CH₂), 2.85 (6H, s, 2×NCH₃), 3.41 (2H, t, J=7.4 Hz, CH₂), 3.68 (2H, t, J=8.7 Hz, CH₂), 4.12 (2H, t, J=8.7 Hz, CH₂), 4.80 (2H, d, J=6.6 Hz, NCH₂), 5.12 (2H, s, OCH₂), 7.2-7.25 (1H, m, aromatic), 7.27-7.34 (3H, m, aromatics), 7.50-7.52 (2H, m, aromatics), 7.55 (1H, dd, J=2.7 Hz and J=8.5 Hz, aromatic), 7.71 (1H, dd, J=5.3 Hz and J=8.6 Hz, aromatic), 8.30 (1H, broad t, NH). MS (ESI⁺) m/e 558 [M+H⁺].

EXAMPLE 14

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-1-butyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (91% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.98 (3H, t, J=7.3 Hz, CH₃), 1.30-1.44 (2H, m, CH₂), 1.56-1.63 (2H, m, CH₂), 2.91 (6H, s, 2×NCH₃), 3.34 (2H, t, J=7.2 Hz, CH₂), 3.62 (2H, t, J=8.4 Hz, CH₂), 4.12 (2H, t, J=8.4 Hz, CH₂), 4.83 (2H, d, J=6.8 Hz, NCH₂), 7.26-7.31 (1H, m, aromatic), 7.55 (1H, dd, J=2.6 Hz and J=8.4 Hz, aromatic), 7.69 (1H, dd, J=5.3 Hz and J=8.6 Hz, aromatic), 8.55 (1H, broad t, NH), 11.40 (1H, s, OH). MS (ESI⁺) m/e 468 [M+H⁺].

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-butyl-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 172-173° C. (ethyl acetate-hexane). (64% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.94 (3H, t, J=7.3 Hz, CH₃), 1.33-1.42 (2H, m, CH₂), 1.55-1.63 (2H, m, CH₂), 2.47 (3H, s, CH₃), 3.42 (2H, t, J=7.4 Hz, CH₂), 3.69 (2H, t, J=8.8 Hz, CH₂), 4.14 (2H, t, J=8.8 Hz, CH₂), 4.42 (2H, d, J=6.3 Hz, NCH₂), 5.11 (2H, s, OCH₂), 7.05 (1H, dd, J=2.7 Hz and J=8.5 Hz, aromatic), 7.11-7.16 (1H, m, aromatic), 7.24-7.28 (3H, m, aromatics), 7.41-7.44 (2H, m, aromatics), 7.68 (1H, dd, J=6.0 Hz and J=8.6 Hz, aromatic), 8.24 (1H, broad t, NH), 8.29 (1H, s, CH). MS (ESI⁺) m/e 532 [M+H⁺]. Anal. Calcd for C₂₈H₃₀FN₇O₃: C 63.26, H 5.68, N 18.44; Found: C 63.18, H 5.79, N 18.32.

EXAMPLE 15

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-1-butyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 214° C. (ethyl acetate). (93% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 0.95 (3H, t, J=7.4 Hz, CH₃), 1.33-1.43 (2H, m, CH₂), 1.56-1.64 (2H, m, CH₂), 2.55 (3H, s, CH₃), 3.38 (2H, t, J=7.2 Hz, CH₂), 3.62 (2H, t, J=8.5 Hz, CH₂), 4.13 (2H, t, J=8.5 Hz, CH₂), 4.49 (2H, d, J=6.5 Hz, NCH₂), 7.09 (1H, dd, J=2.6 Hz and J=8.4 Hz, aromatic), 7.17-7.22 (1H, m, aromatic), 7.69 (1H, dd, J=6.1 Hz and J=8.6 Hz, aromatic), 8.32 (1H, s, CH), 8.57 (1H, broad t, NH), 11.60 (1H, s, OH). MS (ESI⁺) m/e 442 [M+H⁺].

1-Benzyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide. Reaction of N-benzylethylenediamine (15.02 g, 0.10 mol) with cyanogen bromide (10.6 g, 0.10 mol) as described in the preparation of intermediate 6 gave 23.82 g (93% yield) of the title product as white crystals; mp 202-204° C. (ethanol). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.48-3.56 (4H, m, 2×CH₂), 4.57 (2H, m, NCH₂), 7.30-7.44 (5H, m, aromatics), 7.92 and 8.18 (broad s, NH). Anal. Calcd for ClOH₁₃N₃.HBr: C 46.89, H 5.50, N 16.40; Found: C 47.03, H 5.49, N 16.24.

Ethyl 1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (7.66 g, 52.4 mmol), ethyl benzyloxyacetate (10.2 g, 52.5 mmol) and sodium hydride (2.31 g of a 60% dispersion in mineral oil, 57.9 mmol) with 1-benzyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide (13.39 g, 52.5 mmol) as described for intermediate 1 gave 3.98 g (18% yield) of the title ester as white crystals; mp 93° C. (ethyl acetate-hexane).

¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.33 (3H, t, J=7.1 Hz, CH₃), 3.56 (2H, t, J=9.1 Hz, CH₂), 4.12 (2H, t, J=9.1 Hz, CH₂), 4.35 (2H, q, J=7.1 Hz, OCH₂), 4.60 (2H, s, NCH₂), 5.12 (2H, s, OCH₂), 7.3-7.52 (10H, m, aromatics). Anal. Calcd for C₂₃H₂₃N₃O₄: C 68.13, H 5.71, N 10.36; Found: C 67.98, H 5.70, N 10.40.

1-Benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. Saponification of ethyl 1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (2.04 g, 5.04 mmol) as described for intermediate 2 gave 1.90 g (100% yield) of the title acid as white crystals; mp 191° C. (dec), (ethyl acetate). ¹HNMR 400 MHz (DMSO-d,) δ (ppm): 3.58 (2H, t, J=8.8 Hz, CH₂), 4.05 (2H, t, J=8.8 Hz, CH₂), 4.53 (2H, s, NCH₂), 4.93 (2H, s, OCH₂), 7.32-7.45 (10H, m, aromatics), 13.41 (1H, s, OH). Anal. Calcd for C₂₁H₁₉N₃O₄: C 66.83, H 5.07, N 11.13; Found: C 66.73, H 5.16, N 10.97.

N-(4-Fluorobenzyl)-1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 125° C. (ethyl acetate-hexane). (88% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.58 (2H, t, J=8.7 Hz, CH₂), 4.13 (2H, t, J=8.7 Hz, CH₂), 4.51 (2H, d, J=6.1 Hz, NCH₂), 4.60 (2H, s, NCH₂), 5.13 (2H, s, OCH₂), 7.0 (2H, m, aromatics), 7.24-7.38 (10H, m, aromatics), 7.47-7.49 (2H, m, aromatics), 7.71 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₈H₂₆FN₄O₃ [M+H⁺]: 485.1989 ; found: 485.1993.

EXAMPLE 16

N-(4-Fluorobenzyl)-1-benzyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 225° C. (ethyl acetate-hexane). (97% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.53 (2H, t, J=8.6 Hz, CH₂), 4.13 (2H, t, J=8.6 Hz, CH₂), 4.50 (2H, s, NCH₂),4.59 (2H, d, J=6.1 Hz, NCH₂), 7.06 (2H, m, aromatics), 7.25-7.4 (7H, m, aromatics), 7.87 (1H, broad t, NH), 11.60 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₁H₂₀FN₄O₃ [M+H⁺]: 395.1519; found: 395.1508.

N-(4-Fluoro-3-methylbenzyl)-1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals. (81% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.24 (3H, s, CH₃), 3.57 (2H, t, J=8.7 Hz, CH₂), 4.12 (2H, t, J=8.7 Hz, CH₂), 4.47 (2H, d, J=5.6 Hz, NCH₂), 4.58 (2H, s, NCH₂), 5.12 (2H, s, OCH₂), 6.93 (1H, m, aromatic), 7.05-7.12 (2H, m, aromatics), 7.28-7.40 (8H, m, aromatics), 7.47-7.49 (2H, m, aromatics), 7.69 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₉H₂₈FN₄O₃ [M+H⁺]: 499.2145 ; found: 499.2132.

EXAMPLE 17

N-(4-Fluoro-3-methylbenzyl)-1-benzyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 204° C. (dec) (ethyl acetate). (78% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.29 (3H, s, CH₃), 3.53 (2H, t, J=8.5 Hz, CH₂), 4.13 (2H, t, J=8.5 Hz, CH₂), 4.50 (2H, s, NCH₂),4.54 (2H, d, J=6.0 Hz, NCH₂), 7.02 (1H, m, aromatics), 7.1-7.4 (7H, m, aromatics), 7.84 (1H, broad t, NH), 11.63 (1H, s, OH). Anal. Calcd for C₂₂H₂,FN₄O₃: C 64.69, H 5.18, N 13.71; Found: C 64.42, H 5.26, N 13.55.

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (95% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.97 (3H, d, J=5.14 Hz, CH₃), 3.55 (2H, t, J=8.8 Hz, CH₂), 4.09 (2H, t, J=8.8 Hz, CH₂), 4.50 (2H, d, J=6.28 Hz, NCH₂), 4.60 (2H, s, NCH₂), 5.12 (2H, s, OCH₂), 7.03-7.08 (2H, m, aromatics), 7.14 (1H, dd, J=2.5 Hz and J=8.6 Hz, aromatic), 7.28-7.48 (9H, m, NH and aromatics), 7.54-7.57 (2H, m, aromatics), 8.46 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₃₀H₂₉FN₅O₄ [M+H⁺]: 542.2204; found: 542.2214.

EXAMPLE 18

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-1-benzyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 206° C. (dec) (ethyl acetate). (72% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.75 (3H, d, J=4.4 Hz, NCH₃), 3.49 (2H, t, J=8.3 Hz, CH₂), 3.99 (2H, t, J=8.3 Hz, CH₂), 4.54 (2H, d, J=6.0 Hz, NCH₂), 4.57 (2H, s, NCH₂), 7.25-7.4 (8H, m, aromatics), 8.53 (1H, broad, NH), 9.31 (1H, broad, NH), 11.64 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₃H₂₃FN₅O₄ [M+H⁺]: 452.1734 ; found: 452.1720.

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-1-benzyl-6-(benzyloxy)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (91% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.57 (2H, t, J=8.7 Hz, CH₂), 4.04 (2H, t, J=8.7 Hz, CH₂), 4.30 (2H, d, J=6.05 Hz, NCH₂), 4.57 (2H, s, NCH₂), 4.91 (2H, s, OCH₂), 7.16 (1H, m, aromatic), 7.29-7.53 (12H, m, aromatics), 8.23 (1H, s, CH), 8.88 (1H, broad t, NH), 8.99 (1H, s, CH). HRMS (ESI⁺) calculated for C₃₀H₂₇FN₇O₃ [M+H⁺]: 552.2159; found: 552.2173.

EXAMPLE 19

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-1-benzyl-6-hydroxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 242° C. (dec) (ethyl acetate). (74% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.49 (2H, t, J=8.4 Hz, CH₂), 4.00 (2H, t, J=8.4 Hz, CH₂), 4.41 (2H, d, J=6.2 Hz, NCH₂), 4.61 (2H, s, NCH₂), 7.3-7.56 (8H, m, aromatics), 8.24 (1H, s, CH), 9.03 (1H, s, CH), 9.28 (1H, broad t, NH), 11.49 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₃H₂₁FN₇O₃ [M+H⁺]: 462.1690; found: 462.1682.

1-Phenyl-4, 5-dihydro-1H-imidazol-2-amine hydrobromide. Reaction of N-phenylethylenediamine (9.80 g, 0.072 mol) with cyanogen bromide (7.62 g, 0.072 mol) as described in the preparation of intermediate 6 gave 11.76 g (67% yield) of the title product as white crystals from ethanol. ¹HNMR 400 MHz (DMSO-d,) δ (ppm): 3.68 (2H, t, J=8.7 Hz, CH₂), 4.08 (2H, t, J=8.7 Hz, CH₂), 7.40-7.54 (5H, m, aromatics), 8.08 (broad s, NH). MS (ESI⁺) m/e 162 [M+H⁺].

Ethyl 6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (7.06 g, 48.3 mmol), ethyl benzyloxyacetate (9.38 g, 48.3 mmol) and sodium hydride (2.12 g of a 60% dispersion in mineral oil, 53.1 mmol) with 1-phenyl-4,5-dihydro-1H-imidazol-2-amine hydrobromide (11.70 g, 48.3 mmol) as described for intermediate 1 gave 1.99 g (11% yield) of the title ester as white crystals; mp 132-134° C. (ethyl acetate-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.33 (3H, t, J=7.1 Hz, CH₃), 4.23-4.29 (4H, m, 2×CH₂), 4.35 (2H, q, J=7.1 Hz, OCH₂), 5.18 (2H, s, OCH₂), 7.16 (1H,m, aromatic), 7.3-7.53 (7H, m, aromatics), 7.73 (2H, m, aromatics). Anal. Calcd for C₂₂H₂₁N₃O₄: C 67.50, H 5.40, N 10.73; Found: C 67.44, H 5.68, N 10.73.

6-(Benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. Saponification of ethyl 6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (1.94 g, 4.95 mmol) as described for intermediate 2 gave 1.78 g (98% yield) of the title acid as white crystals. ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 4.17-4.20 (4H, m, 2×CH₂), 5.00 (2H, s, OCH₂), 7.13 (1H,m, aromatic), 7.35-7.46 (7H, m, aromatics), 7.78 (2H, m, aromatics), 13.52 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₀H₁₈N₃O₄ [M+H⁺]: 364.1297 ; found: 364.1292.

N-(4-Fluorobenzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 199-200° C. (dichloromethane-ethyl acetate). (85% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 4.22-4.31 (4H, m, 2×CH₂), 4.51 (2H, d, J=6.1 Hz, NCH₂), 5.19 (2H, s, OCH₂), 7.02 (2H, m, aromatics), 7.14-7.5 (10H, m, aromatics), 7.62 (1H, broad t, NH), 7.67-7.71 (2H, m, aromatics). HRMS (ESI⁺) calculated for C₂₇H₂₄FN₄O₃ [M+H⁺]: 471.1832 ; found: 471.1833.

EXAMPLE 20

N-(4-Fluorobenzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (dichloromethane-hexane). (81% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 4.16 (2H, m, CH₂), 4.28 (2H, m, CH₂), 4.56 (2H, d, J=6.0 Hz, NCH₂), 7.05 (2H, m, aromatics), 7.15 (1H, m, aromatic), 7.30 (2H, m, aromatics), 7.37 (2H, m, aromatics), 7.50 (2H, m, aromatics), 7.72 (1H, broad t, NH),11.69 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₀H₁₈FN₄O₃ [M+H⁺]: 381.1363 ; found: 381.1378.

N-(4-Fluoro-3-methylbenzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 147° C. (ethyl acetate). (86% yield). ¹HNMR 400 MHz (DMSO-dr) δ (ppm): 2.12 (3H, s, CH₃), 4.12-4.25 (4H, m, 2×CH₂), 4.38 (2H, d, J=6.1 Hz, NCH₂), 4.97 (2H, s, OCH₂), 6.99 (1H, m, aromatic), 7.12-7.21 (3H, m, aromatics), 7.33-7.43 (7H, m, aromatics), 7.81 (2H, m, aromatics), 8.82 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₈H₂₆FN₄O₃ [M+H⁺]: 485.1989 ; found: 485.1976.

EXAMPLE 21

N-(4-Fluoro-3-methylbenzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (61% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.22 (3H, s, CH₃), 4.14 (4H, broad s, 2×CH₂), 4.50 (2H, d, J=5.6 Hz, NCH₂), 7.11 (2H, m, aromatics), 7.20 (2H, m, aromatics), 7.4 (2H, m, aromatics), 7.8 (2H, m, aromatics), 8.83 (1H, broad t, NH), 1 2.06 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₁H₂₀FN₄O₃ [M+H⁺]: 95.1519 ; found: 395.1521.

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 194-195° C. (ethyl acetate). (76% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.79 (3H, d, J=4.52 Hz, NCH₃), 4.14-4.25 (4H, m, 2×CH₂), 4.49 (2H, d, J=6.5 Hz, NCH₂), 5.0 (2H, s, OCH₂), 7.08 (1H, m, aromatic), 7.14 (1H, m, aromatic), 7.29 (1H, dd, J=2.7 Hz and J=9.3 Hz, aromatic), 7.33-7.45 (8H, m, aromatics), 7.82 (2H, m, aromatics), 8.52 (1H, broad q, NH), 8.80 (1H, broad t, NH). Anal. Calcd for C₂₉H₂₆FN₅O₄: C 66.02, H 4.96, N 13.27; Found: C 65.77, H 5.19, N 13.28.

EXAMPLE 22

N-(4-Fluoro-2-(methylcarbamoyl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (60% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.88 (3H, d, J=4.5 Hz, NCH₃), 4.12 (4H, broad s, 2×CH₂), 4.54 (2H, d, J=6.6 Hz, NCH₂), 7.11 (1H, m, aromatic), 7.3-7.5 (5H, m, aromatics), 7.86 (2H, m, aromatics), 8.68 (H, broad q, NH), 9.18 (1H, broad, NH), 12.0 (11H, s, OH). HRMS (ESI⁺) calculated for C₂₂H₂₁FN₅O₄ [M+H⁺]: 438.1578 ; found: 438.1576.

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 187-190° C. (ethyl acetate). (74% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 4.13-4.25 (4H, m, 2×CH₂), 4.33 (2H, d, J=6.08 Hz, NCH₂), 5.0 (2H, s, OCH₂), 7.11-7.17 (2H, m, aromatics), 7.32-7.43 (7H, m, aromatics), 7.47-7.58 (2H, m, aromatics), 7.76-7.81 (2H, m, aromatics), 8.29 (1H, s, CH), 8.80 (1H, broad t, NH), 9.0 (1H, s, CH). HRMS (ESI⁺) calculated for C₂₉H₂₅FN₇O₃ [M+H⁺]: 538.2003 found: 538.1993.

EXAMPLE 23

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (dichloromethane-ethanol). (53% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 4.13 (4H, s, 2×CH₂), 4.46 (2H, d, J=6.1 Hz, NCH₂), 711 (1H, m, aromatic), 7.34-7.45 (3H, m, aromatics), 7.61 (2H, m, aromatics), 7.77 (2H, m, aromatics), 8.29 (1H, s, CH), 8.81 (1H, broad t, NH), 9.09 (1H, s, CH), 11.89 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₂H₁₉FN₇O₃ [M+H⁺]: 448.1533 ; found: 448.1550.

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 147-148° C. (ethyl acetate). (84% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.33 (3H, s, CH₃),4.20-4.32 (4H, m, 2×CH₂), 4.46 (2H, d, J=6.5 Hz, NCH₂), 5.21 (2H, s, OCH₂), 7.07 (1H ,dd, J=2.5 Hz and J=8.6 Hz, aromatic), 7.10-7.18 (2H, m, aromatics), 7.27-7.35 (5H, m, aromatics), 7.42-7.46 (2H, m, aromatics), 7.69-7.73 (3H, m, aromatics), 8.26 (1H, s, CH), 8.29 (1H, broad t, NH). MS (ESI⁺) m/e 552 [M+H⁺].

EXAMPLE 24

N-(4-Fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (71% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.23 (3H, s, CH₃), 4.18 (2H, m, CH₂), 4.29 (2H, m, CH₂), 4.49 (2H, d, J=6.6 Hz, NCH₂), 7.09-7.15 (2H, m, aromatics), 7.18-7.23 (1H, m, aromatic), 7.28-7.32 (2H, m, aromatics), 7.6-7.7 (3H, m, aromatics), 8.33 (1H, s, CH), 8.62 (1H, broad t, NH), 11.91 (1H, s, OH). MS (ESI⁺) m/e 462 [M+H⁺].

N-(4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 181° C. (ethyl acetate). (72% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.44 (3H, s, CH₃),4.23-4.32 (6H, m, 2×CH₂ and NCH₂), 5.22 (2H, s, OCH₂), 7.00 (1H , dd, J=2.7 Hz and J=8.5 Hz, aromatic), 7.16-7.22 (2H, m, aromatics), 7.28-7.33 (3H, m, aromatics), 7.39-7.43 (2H, m, aromatics), 7.49-7.51 (2H, m, aromatics), 7.69-7.73 (3H, m, aromatics), 7.81 (1H, s, CH), 8.05 (1H, broad t, NH). Anal. Calcd for C₃₀H₂₆FN₇O₃: C 65.32, H 4.75, N 17.77; Found: C 65.03, H 4.56, N 17.49.

EXAMPLE 25

N-(4-Fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (65% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.50 (3H, s, CH₃), 4.19 (2H, m, CH₂), 4.28 (4H, m, 2×CH₂), 7.04 (1H, dd, J=2.5 Hz and J=8.3 Hz, aromatic), 7.15-7.27 (2H, m, aromatics), 7.44 (2H, m, aromatics), 7.65-7.75 (2H, m, aromatics), 7.90 (1H, s, CH), 8.42 (1H, broad t, NH), 11.87 (1H, s, OH). MS (ESI⁺) m/e 462 [M+H⁺].

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (acetonitrile). (75% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.80 (6H, s, 2×NCH₃), 4.16-4.26 (4H, m, 2×CH₂), 4.72 (2H, d, J=6.4 Hz, NCH₂), 5.03 (2H, s, OCH₂), 7.13-7.23 (2H, m, aromatics), 7.32-7.46 (7H, m, aromatics), 7.57-7.63 (2H, m, aromatics), 7.80-7.82 (2H, m, aromatics), 8.83 (1H, broad t, NH). HRMS (ESI⁺) calculated for C₂₉H₂₉FN₅O₅S [M+H⁺]: 578.1873 ; found: 578.1852.

EXAMPLE 26

N-(4-Fluoro-2-(N,N-dimethylsulfamoyl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (90% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.85 (6H, s, 2×NCH₃), 4.13 (4H, s, 2×CH₂), 4.82 (2H, d, J=6.6 Hz, NCH₂), 7.11 (1H, m, aromatic), 7.42 (2H, m, aromatics), 7.55-7.65 (3H, m, aromatics), 7.78 (2H, m, aromatics), 8.77 (1H, broad t, NH), 11.76 (1H, s, OH). HRMS (ESI⁺) calculated for C₂₂H₂₃FN₅O₅S [M+H⁺]: 488.1404; found: 488.1419.

N-(4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (58% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 2.23 (2H, m, CH₂), 2.58 (2H, t, J=8.0 Hz, CH₂), 3.79 (2H, t, J=7.0 Hz, CH₂), 4.15-4.30 (4H, m, 2×CH₂), 4.46 (2H, d, J=6.0 Hz, NCH₂), 5.22 (2H, s, OCH₂), 6.91 (1H, dd, J=2.6 Hz and J=9.4 Hz, aromatic), 6.99 (1H, m, aromatic), 7.14 (1H, m, aromatic), 7.30-7.46 (5H, m, aromatics), 7.44 (1H, dd, J=6.1 Hz and J=8.6 Hz, aromatic), 7.50-7.52 (2H, m, aromatics), 7.69-7.71 (2H, m, aromatics), 7.95 (1H, broad t, NH). MS (ESI⁺) m/e 554 [M+H⁺].

EXAMPLE 27

N-(4-Fluoro-2-(2-oxopyrrolidin-1-yl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (78% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 2.15 (2H, m, CH₂), 2.55 (2H, t, J=7.9 Hz, CH₂), 3.81 (2H, t, J=6.9 Hz, CH₂), 4.13 (4H, broad s, 2×CH₂), 4.41 (2H, d, J=6.4 Hz, NCH₂), 7.07 (1H, m, aromatic), 7.18 (1H, m, aromatic), 7.28 (1H, dd, J=2.5 Hz and J=10 Hz, aromatic), 7.36-7.40 (2H, m, aromatics), 7.45 (1H, dd, J=6.5 Hz and J=8.6 Hz, aromatic), 7.82-7.84 (2H, m, aromatics), 8.87 (1H, broad t, NH), 12.10 (1H, s, OH). MS (ESI⁺) m/e 464 [M+H⁺].

N-(4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl)-6-(benzyloxy)-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (ethyl acetate). (22% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.10 (2H, t, J=4.4 Hz, CH₂), 3.73 (2H, t, J=4.4 Hz, CH₂), 4.19-4.31 (4H, m, 2×CH₂), 4.60 (2H, d, J=6.3 Hz, NCH₂), 5.21 (2H, s, OCH₂), 6.88 (1H, m, aromatic), 6.93 (1H, dd, J=2.4 Hz and J=9.7 Hz, aromatic), 7.16 (1H, m, aromatic), 7.29-7.31 (3H, m, aromatics), 7.39-7.43 (2H, m, aromatics), 7.47-7.48 (2H, m, aromatics), 7.54 (1H, dd, J=6.3 Hz and J=8.3 Hz, aromatic), 7.70-7.72 (2H, m, aromatics), 8.25 (1H, broad t, NH). MS (ESI⁺) m/e 540 [M+H⁺].

EXAMPLE 28

N-(4-Fluoro-2-(2-oxoazetidin-1-yl)benzyl)-6-hydroxy-5-oxo-1-phenyl-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals (dichloromethane). (67% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.17 (2H, t, J=4.4 Hz, CH₂), 3.82 (2H, t, J=4.4 Hz, CH₂), 4.13 (4H, broad s, 2×CH₂),4.59 (2H, d, J=6.6 Hz, NCH₂), 7.07-7.11 (2H, m, aromatics), 7.23 (1H, dd, J=2.5 Hz and J=10.4 Hz, aromatic), 7.37-7.41 (2H, m, aromatics), 7.45 (1H, dd, J=6.6 Hz and J=8.6 Hz, aromatic), 7.82-7.84 (2H, m, aromatics), 9.04 (1H, broad t, NH), 12.03 (1H, s, OH). MS (ESI⁺) m/e 450 [M+H⁺].

1-(2-Methoxyethyl)-4,5-dihydro-1H-imidazol-2-amine hydrobromide. Reaction of N-(2-methoxyethyl)ethylenediamine (16.0 g, 0.135 mol) (R. C. F. Jones and J. R. Nichols, Tetrahedron Lett., 1990, 31, 1767-1770) with cyanogen bromide (14.34 g, 0.135 mol) as described in the preparation of intermediate 6 gave 26.86 g (88% yield) of the title product as large white prisms (ethanol); mp 143-145° C.

¹HNMR 400.¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.28 (3H, s, OCH₃), 3.48 (4H, s, 2×CH₂), 3.52 (2H, m, CH₂), 3.67 (2H, m, CH₂), 7.87 (broad s, NH). Anal. Calcd for C₆H₁₃N₃O. HBr: C 32.15, H 6.29, N 18.75; Found: C 32.23, H 6.14, N 18.85.

Ethyl 6-(benzyloxy)-1-(2-methoxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (16.95 g, 0.116 mol), ethyl benzyloxyacetate (22.53 g, 0.116 mol) and sodium hydride (5.10 g of a 60% dispersion in mineral oil, 0.127 mol) with 1-(2-methoxyethyl)-4,5-dihydro-1H-imidazol-2-amine hydrobromide (26.0 g, 0.116 mol) as described for intermediate 1 gave 5.37 g (12% yield) of the title ester as a clear oil. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.31 (3H, t, J=7.1 Hz, CH₃), 3.38 (3H, s, OCH₃), 3.61 (4H, s, 2×CH₂), 3.84 (2H, t, J=8.9 Hz, CH₂), 4.14 (2H, t, J=8.9 Hz, CH₂), 4.32 (2H, q, J=7.1 Hz, OCH₂), 5.09 (2H, s, OCH₂), 7.3-7.38 (3H, m, aromatics), 7.49 (2H, m, aromatics). MS (ESI⁺) m/e 374 [M+H⁺].

6-(Benzyloxy)-1-(2-methoxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. White crystals; mp 125-126° C. (ethyl acetate). (97% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.38 (3H, s, OCH₃), 3.61 (4H, s, 2×CH₂), 3.86 (2H, t, J=9.0 Hz, CH₂), 4.16 (2H, t, J=9.0 Hz, CH₂), 5.26 (2H, s, OCH₂), 7.35-7.40 (3H, m, aromatics), 7.57 (2H, m, aromatics). Anal. Calcd for C₁₇H₁₉N₃O₅: C 59.12, H 5.54, N 12.16; Found: C 59.04, H 5.55, N 12.10.

N-(4-Fluorobenzyl)-6-(benzyloxy)-1-(2-methoxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 150° C. (ethyl acetate). (79% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.38 (3H, s, OCH₃), 3.61 (4H, s, 2×CH₂), 3.84 (2H, t, J=8.9 Hz, CH₂), 4.14 (2H, t, J=8.9 Hz, CH₂), 4.49 (2H, d, J=6.1 Hz, NCH₂), 5.10 (2H, s, OCH₂), 6.99 (2H, m, aromatics), 7.24 (2H, m, aromatics), 7.33-7.36 (3H, m, aromatics), 7.43-7.45 (2H, m, aromatics), 7.67 (1H, broad t, NH). Anal. Calcd for C₂₄H₂₅FN₄O₄: C 63.70, H 5.56, N 12.38; Found: C 64.00, H 5.41, N 12.10.

EXAMPLE 29

N-(4-Fluorobenzyl)-6-hydroxy-1-(2-methoxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 166° C. (ethanol). (96% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.38 (3H, s, OCH₃), 3.51 (2H, m, CH₂), 3.59 (2H, m, CH₂), 3.76 (2H, t, J=8.6 Hz, CH₂), 4.14 (2H, t, J=8.6 Hz, CH₂), 4.58 (2H, d, J=6.6 Hz, NCH₂), 7.07 (2H, m, aromatics), 7.32 (2H, m, aromatics), 7.85 (1H, broad t, NH), 11.57 (1H, s, OH). Anal. Calcd for C₁₇H₁₉FN₄O₄: C 56.34, H 5.28, N 15.46; Found: C 56.39, H 5.37, N 15.27.

1-(2-Hydroxyethyl)-4,5-dihydro-1H-imidazol-2-amine hydrobromide. Reaction of 2-(2-aminoethylamino)ethanol (8.0 g, 76.8 mmol) with cyanogen bromide (8.13 g, 76.8 mmol) as described in the preparation of intermediate 6 gave 13.27 g (82% yield) of the title product as large white prisms (ethanol); mp 112-115° C. ¹HNMR 400.¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.36 (2H, t, J=5.3 Hz, CH₂), 3.50-3.58 (4H, m, 2×CH₂), 3.69 (2H, m, CH₂), 4.97 (1H, t, J=5.0 Hz, OH), 7.73 and 7.85 (broad s, NH). Anal. Calcd for C₅H₁₁N₃0.HBr: C 28.58, H 5.75, N 20.00; Found: C 28.79, H 5.58, N 20.12.

Ethyl 6-(benzyloxy)-]-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. Reaction of the adduct of diethyl oxalate (14.61 g, 0.10 mol), ethyl benzyloxyacetate (19.42 g, 0.10 mol) and sodium hydride (4.40 g of a 60% dispersion in mineral oil, 0.11 mol) with 1-(2-hydroxyethyl)-4,5-dihydro-1H-imidazol-2-amine hydrobromide (21.0 g, 0.10 mol) as described for intermediate 1 gave 3.37 g (9% yield) of the title ester as white crystals; mp 104-106° C. (ethyl acetate-hexane). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.32 (3H, t, J=7.1 Hz, CH₃), 3.53 (2H, m, CH₂), 3.83 (2H, t, J=8.9 Hz, CH₂), 3.90 (2H, m, CH₂), 4.19 (2H, t, J=8.9 Hz, CH₂), 4.32 (2H, q, J=7.1 Hz, OCH₂), 5.11 (2H, s, OCH₂), 7.35-7.40 (3H, m, aromatics), 7.51 (2H, m, aromatics). Anal. Calcd for C₁8H₂₁N₃O₅: C 60.16, H 5.89, N 11.69; Found: C 60.24, H 5.89, N 11.77.

6-(Benzyloxy)-1-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylic acid. White crystals (ethyl acetate). (80% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.36 (2H, t, J=5.8 Hz, CH₂), 3.58 (2H, broad t, CH₂), 3.76 (2H, t, J=9.1 Hz, CH₂), 4.02 (2H, t, J=9.1 Hz, CH₂), 4.85 (1H, broad, OH), 4.90 (2H, s, OCH₂), 7.34-7.43 (SH, m, aromatics), 13.3 (H, broad, OH). MS (ESI⁺) m/e 332 [M+H⁺].

Ethyl 6-hydroxy-1-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate. A solution of ethyl 6-(benzyloxy)-1-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (1.40 g, 3.89 mmol) in a mixture of ethyl acetate (300 ml) and ethanol (75 ml) at 25° C. was hydrogenated over 10% palladium on activated carbon (200 mg) and under one atmosphere of hydrogen for four hours to give 1.05 g (100% yield) of the title compound as light yellow needles; mp 155-156° C. (ethyl acetate). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 1.44 (3H, t, J=7.1 Hz, CH₃), 3.46 (2H, m, CH₂), 3.75 (2H, t, J=8.3 Hz, CH₂), 3.92 (2H, m, CH₂), 4.20 (2H, t, J=8.3 Hz, CH₂), 4.43 (2H, q, J=7.1 Hz, OCH₂), 10.20 (1H, s, OH). Anal. Calcd for C₁₁H₁₅N₃O₅: C 49.06, H 5.61, N 15.60; Found: C 49.09, H 5.73, N 15.58.

EXAMPLE 30

N-(4-Fluorobenzyl)-6-hydroxy-1-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. A solution of ethyl 6-hydroxy-1-(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxylate (0.110 g, 0.408 mmol) and 4-fluorobenzylamine (0.200 g, 1.6 mmol) in anhydrous ethanol (5 ml) was heated under reflux for 6 h. The reaction mixture was then diluted with ethyl acetate, washed successively with 0.1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. Crystallization of the residual solid from ethanol gave 0.116 g (82% yield) of the title amide as white cubes; mp 203° C. ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.54 (2H, t, J=5.0 Hz, CH₂), 3.80 (2H, t, J=8.5 Hz, CH₂), 3.89 (2H, t, J=5.0 Hz, CH₂), 4.15 (2H, t, J=8.5 Hz, CH₂), 4.57 (2H, d, J=6.0 Hz, NCH₂), 7.07 (2H, m, aromatics), 7.34 (2H, m, aromatics), 7.92 (1H, broad t, NH), 11.68 (1H, s, OH). Anal. Calcd for C₁₆H₁₇FN₄O₄: C 55.17, H 4.92, N 16.08; Found: C 55.22, H 5.06, N 15.89.

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-(benzyloxy)-1-(2-hydroxyethyl)-5-oxo-]1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White solid (67% yield). ¹HNMR 400 MHz (CDCl₃) δ (ppm): 3.55 (2H, t, J=5.0 Hz, CH₂), 3.81 (2H, t, J=8.7 Hz, CH₂), 3.88 (2H, t, J=5.0 Hz, CH₂), 4.17 (2H, t, J=8.7 Hz, CH₂), 4.42 (2H, d, J=6.1 Hz, NCH₂), 5.13 (2H, s, OCH₂), 7.06 (1H, dd, J=2.5 Hz and J=8.6 Hz, aromatic), 7.18 (1H, m, aromatic), 7.25-7.31 (3H, m, aromatics), 7.39-7.41 (2H, m, aromatics), 7.69 (1H, dd, J=5.5 Hz and J=8.6 Hz, aromatic), 7.98 (1H, s, CH), 8.27 (1H, broad t, NH), 8.38 (1H, s, CH). MS (ESI⁺) m/e 506 [M+H⁺].

EXAMPLE 31

N-(4-Fluoro-2-(1H-1,2,4-triazol-1-yl)benzyl)-6-hydroxy--(2-hydroxyethyl)-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-a]pyrimidine-7-carboxamide. White crystals; mp 220-222° C. (ethanol). (86% yield). ¹HNMR 400 MHz (DMSO-d₆) δ (ppm): 3.42 (2H, t, J=5.8 Hz, CH₂), 3.62 (2H, m, CH₂), 3.68 (2H, t, J=8.5 Hz, CH₂), 3.98 (2H, t, J=8.5 Hz, CH₂), 4.41 (2H, d, J=6.0 Hz, NCH₂), 4.79 (1H, t, J=5.6 Hz, OH), 7.42 (1H, m, aromatic), 7.53 (1H, dd, J=6.1 Hz and J=8.6 Hz, aromatic), 7.57 (1H, dd, J=2.7 Hz and J=9.3 Hz, aromatic), 8.34 (1H, s, CH), 9.06 (1H, s, CH), 9.16 (1H, broad t, NH), 11.43 (1H, s, OH). MS (ESI⁺) m/e 416 [M+H⁺].

Some other examples of formula I compounds are listed in table 4.

TABLE 4
Example Structure
32
33
34
35
36
37
38
39
40
41
42
43

Claims

1. A compound of Formula I

2. A compound of claim 1 where R1 is

3. A compound of claim 1 where R1 is

4. A compound of claim 1 where R1 is

5. A compound of claim 1 where R2 is hydrogen.

6. A compound of claim 1 where R3 is triazinyl substituted with 0-1 methyl groups; R4 is hydrogen, chloro, flouro, or methyl; and R5 is hydrogen.

7. A compound of claim 1 where R is hydrogen or alkyl.

8. A compound of claim 1 where R7 is alkyl.

9. A compound of claim 1 where X—Y—Z is N(R9)CH2CH2, N(R9)CH2CH2CH2, or N(R9)CH2CH2CH2CH2.

10. A compound of claim 1 where R9 is alkyl, cycloalkyl, hydroxyalkyl, (alkoxy)alkyl, phenyl, or benzyl.

11. A compound of claim 1 selected from the group consisting of N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-methyl-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-methyl-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-methyl-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-(phenylmethyl)-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-(phenylmethyl)-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-(phenylmethyl)-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-(phenylmethyl)-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[2-[(dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[2-[(dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-hydroxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[[2-[(dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-cyclohexyl-N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-cyclohexyl-N-[(4-fluoro-3-methylphenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-cyclohexyl-N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[[4-fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-cyclohexyl-N-[[2-[(dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(2-oxo-1-azetidinyl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-hydroxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(2-oxo-1-pyrrolidinyl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[(4-fluorophenyl)methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(1-methylethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-[(methylamino)carbonyl]phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[2-[(dimethylamino)sulfonyl]-4-fluorophenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(methylsulfonyl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenyl-imidazo[1,2-a]pyrimidine-7-carboxamide; 1-butyl-N-[[4-fluoro-2-(1H-1,2,4-triazol-1-yl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; N-[[4-fluoro-2-(methylsulfonyl)phenyl]methyl]-1,2,3,5-tetrahydro-6-hydroxy-1-(2-methoxyethyl)-5-oxo-imidazo[1,2-a]pyrimidine-7-carboxamide; and [5-fluoro-2-[[[(1,2,3,5-tetrahydro-6-hydroxy-5-oxo-1-phenylimidazo[1,2-a]pyrimidin-7-yl)carbonyl]amino]methyl]phenyl]-phosphonic acid, dimethyl ester; or a pharmaceutically acceptable salt thereof

12. A composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

13. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

14. The method of claim 13, further comprising a therapeutically effective amount of one or more other HIV treatment agents selected from the group consisting of HIV protease inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV-entry inhibitors, HIV integrase inhibitors, immunomodulators, or a combination thereof.